Qyuns Therapeutics Co. Ltd. (2509)

Overview

Founded in 2015 and based in Taizhou, China, Qyuns Therapeutics Co., Ltd. positions itself as a clinical-stage biotech innovator, primarily focusing on the development of biologic therapies intended to combat a range of autoimmune and allergic conditions within the People's Republic of China. Utilizing advanced scientific research and innovative biotechnological approaches, the company endeavors to address the unmet medical needs associated with these complex diseases, striving to lead the way in the discovery of novel and effective treatments.

Products and Services

• QX002N: A pioneering interleukin-17A (IL-17A) inhibitor, designed to target and mitigate the impacts of ankylosing spondylitis (AS) and lupus nephritis (LN), showcasing Qyuns Therapeutics' commitment to addressing severe autoimmune disorders.
• QX005N: This monoclonal antibody (mAb) sets its sights on blocking IL-4Ra, potentially offering a novel approach to treating a spectrum of conditions, including atopic dermatitis (AD), prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), asthma, and even chronic obstructive pulmonary disease (COPD).
• QX001S: An IL-12/IL-23p40 inhibitor, this candidate drug is being explored for its efficacy in treating psoriasis (Ps) and potentially providing relief for individuals battling ulcerative colitis (UC) or Crohn's disease (CD).
• QX004N: This IL-23p19 inhibitor underscores the company’s focus on psoriasis (Ps) and Crohn's disease (CD), illustrating the breadth of Qyuns Therapeutics’ pipeline aimed at providing solutions for dermatological conditions.
• QX006N: Targeting IFNAR1, this monoclonal antibody represents a strategic move towards combating systemic lupus erythematosus (SLE), a condition that poses significant treatment challenges.
• QX008N: A humanized IgG1 mAb that zeroes in on thymic stromal lymphopoietin, with a therapeutic focus on moderate-to-severe asthma and COPD, highlighting the company's commitment to respiratory health.
• QX007N: With an aim at IL-33, this development seeks to broaden the therapeutic options available for individuals living with chronic respiratory ailments such as COPD and asthma.
• QX013N: By targeting c-kit through a humanized IgG1 mAb, this drug candidate is poised to offer new hope for patients suffering from chronic spontaneous urticaria (CSU), demonstrating the company’s dedication to tackling a variety of allergic conditions.
• QX010N: An interleukin-31 receptor (IL-31R) inhibitor, currently in the pipeline with a focus on alleviating pruritus, a frequent and often distressing symptom associated with numerous dermatological and systemic diseases.

In addition to these promising product candidates, Qyuns Therapeutics Co., Ltd. leverages its multi-faceted capabilities in the research, development, and production of pharmaceutical products, complemented by the provision of technical consultation services, to fuel its mission of bringing transformative treatments to market.